A bevy of U.S.-based firms – notably Alnylam Pharmaceuticals Inc., of Cambridge, Mass. – together with London-based Silence Therapeutics plc and, more recently, South Korean start-up BioMolecular Therapeutics, have been striving mightily to become first to market using RNAi-based platform technology to treat cancer.